Prognosis Factors in Patients with Copd and Atrial Fibrillation – Mini Review
By:
References
- Radovanovic D, Contoli M, Braido F, Maniscalco M, Micheletto C, Solidoro P, Santus P, Carone M. Future Perspectives of Revaluating Mild COPD. Respiration. 2022; 101(7):688-696.
- Sandelowsky H, Weinreich UM, Aarli BB, et al. COPD -do the right thing. BMC Fam Pract. 2021; 22(1):244.
- Ulmeanu R, Fildan AP, Rajnoveanu RM, et al. Romanian clinical guideline for diagnosis and treatment of COPD. J Int Med Res 2020; 48(8): 300060520946907.
- Simons SO, Elliott A, Sastry M, et al. Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective. Eur Heart J. 2021; 42(5):532-540.
- Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370:741–750.
- Sandelowsky H, Ställberg B, Nager A, Hasselström J. The prevalence of undiagnosed chronic obstructive pulmonary disease in a primary care population with respiratory tract infections - a case fnding study. BMC Fam Pract. 2011; 12:122.
- Kaplan A, Thomas M. Screening for COPD: the gap between logic and evidence. Eur Respir Rev. 2017;26(143):160113.
- Grymonprez M, Vakaet V, Kavousi M, et al. Chronic obstructive pulmonary disease and the development of atrial fibrillation. Int J Cardiol. 2019; 276:118-124.
- Chao TF, Hung CL, Chen SJ, et al. The association between hyperuricemia, left atrial size and new-onset atrial fibrillation. Int J Cardiol. 2013; 168(4):4027-32.
- McManus DD, Yin X, Gladstone R, et al. Alcohol Consumption, Left Atrial Diameter, and Atrial Fibrillation. J Am Heart Assoc. 2016; 5(9):e004060.
- van der Velden RMJ, Hermans ANL, Pluymaekers NAHA, et al. Dyspnea in patients with atrial fibrillation: Mechanisms, assessment and an interdisciplinary and integrated care approach. Int J Cardiol Heart Vasc. 2022; 42:101086.
- Guerra F, Brambatti M, Nieuwlaat R, et al. Symptomatic atrial fibrillation and risk of cardiovascular events: data from the Euro Heart Survey. Europace. 2017; 19(12):1922-9.
- Tsigkas G, Apostolos A, Despotopoulos S, et al. Heart failure and atrial fibrillation: new concepts in pathophysiology, management, and future directions, Heart Fail Rev. 2022; 27(4): 1201–1210.
- Romiti GF, Corica B, Pipitone E, et al. Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. Eur Heart J. 2021; 14;42(35):3541-3554.
- Aisanov Z, Khaltaev N. Management of cardiovascular comorbidities in chronic obstructive pulmonary disease patients. J Thorac Dis. 2020; 12(5):2791-2802.
- Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011; 378:1015-26.
- Papaioannou AI, Mazioti A, Kiropoulos T, et al. Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir Med 2010; 104:275-82.
- Van Wagoner DR, Chung MK. Inflammation, Inflammasome Activation, and Atrial Fibrillation. Circulation. 2018; 138(20):2243-2246.
- Marcus GM, Smith LM, Ordovas K, et al. Intra and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm. 2010; 7:149–154.
- Zhou X, Dudley SC Jr. Evidence for Inflammation as a Driver of Atrial Fibrillation. Front Cardiovasc Med. 2020; 7:62.
- Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir. Med. 2021; 9(11): 1288–1298.
- Matarazzo L, Hernandez Santana YE, Walsh PT, Fallon PG. The IL-1 cytokine family as custodians of barrier immunity. Cytokine. 2022; 154:155890.
- Hak Ł, Myśliwska J, Wieckiewicz J, et al. Interleukin-2 as a predictor of early postoperative atrial fibrillation after cardiopulmonary bypass graft (CABG). J Interferon Cytokine Res. 2009; 29(6):327-32.
- Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol. 2004; 148:462–466.
- Hlapčić I, Belamarić D, Bosnar M, et al. Combination of Systemic Inflammatory Biomarkers in Assessment of Chronic Obstructive Pulmonary Disease: Diagnostic Performance and Identification of Networks and Clusters. Diagnostics (Basel). 2020; 10(12):1029.
- Rennard SI, Locantore N, Delafont B, et al. Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis. Ann Am Thorac Soc. 2015; 12: 303–312.
- Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol. 2021; 18(1):58-68.
- Ridker PM, Libby P, MacFadyen JG, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018; 39(38):3499-3507.
- Rafaqat S, Sharif S, Majeed M, et al. Biomarkers of Metabolic Syndrome: Role in Pathogenesis and Pathophysiology Of Atrial Fibrillation. J Atr Fibrillation. 2021; 14(2):20200495.
- Psychari SN, Apostolou TS, Sinos L, et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol. 2005; 95(6):764–767.
- Liuba I, Ahlmroth H, Jonasson L, et al. Source of inflammatory markers in patients with atrial fibrillation. Europace. 2008; 10(7):848-53.
- Miller J, Edwards LD, Agustí A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013; 107:1376–84.
- Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128–38.
- Fermont JM, Masconi KL, Jensen MT, et al. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis. Thorax. 2019; 74(5):439-446.
- Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185:1065–72.
- Zeng YY, Hu WP, Zuo YH, Wang XR, Zhang J. Altered serum levels of type I collagen turnover indicators accompanied by IL-6 and IL-8 release in stable COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:163-168.
- Regan EA, Hersh CP, Castaldi PJ, et al. Omics and the Search for Blood Biomarkers in Chronic Obstructive Pulmonary Disease. Insights from COPDGene. Am J Respir Cell Mol Biol. 2019; 61(2):143-149.
- Shyam Prasad Shetty B, Chaya SK, Kumar V S, et al. Inflammatory Biomarkers Interleukin 1 Beta (IL-1β) and Tumour Necrosis Factor Alpha (TNF-α) Are Differentially Elevated in Tobacco Smoke Associated COPD and Biomass Smoke Associated COPD. Toxics. 2021; 9(4):72.
- Eagan TM, Gabazza EC, D'Alessandro-Gabazza C, et al. TNF-α is associated with loss of lean body mass only in already cachectic COPD patients. Respir Res. 2012; 13(1):48.
- Shyam Prasad Shetty B, Chaya SK, Kumar V S, et al. Inflammatory Biomarkers Interleukin 1 Beta (IL-1β) and Tumour Necrosis Factor Alpha (TNF-α) Are Differentially Elevated in Tobacco Smoke Associated COPD and Biomass Smoke Associated COPD. Toxics. 2021; 9(4): 72.
- Derella CC, Tingen MS, Blanks A, et al. Smoking cessation reduces systemic inflammation and circulating endothelin-1. Sci Rep. 2021; 11(1):24122.
- Terzano C, Romani S, Conti V, et al. Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci. 2014; 18(19):2908-17.
- Goudis CA. Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. J Cardiol. 2017; 69(5):699-705.
- Bodez D, Damy T, Soulat-Dufour L, Meuleman C, Cohen A. Consequences of obstructive sleep apnoea syndrome on left ventricular geometry and diastolic function. Arch Cardiovasc Dis. 2016; 109(8–9):494–503.
- Pauklin P, Zilmer M, Eha J, et al. Markers of Inflammation, Oxidative Stress, and Fibrosis in Patients with Atrial Fibrillation. Oxid Med Cell Longev. 2022; 2022:4556671.
- Liguori I, Russo G, Curcio F, et al. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018; 13:757-772.
- Choudhury G, MacNee W. Role of inflammation and oxidative stress in the pathology of ageing in COPD: potential therapeutic interventions. COPD. 2017; 14(1):122–135.
- Liu CC, Chen YH, Chang YH, et al. New-Onset Atrial Fibrillation Is a Risk Factor of Ischemic Stroke in Chronic Obstructive Pulmonary Disease. Healthcare (Basel). 2022; 10(2):381.
Language: English
Page range: 73 - 80
Published on: Apr 15, 2023
Published by: Romanian Society of Internal Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2023 Elena-Andreea Moales, Ioana Mădălina Zota, Laura Carina Tribus, Corina Dima Cozma, Florin Mitu, published by Romanian Society of Internal Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.